Flare Therapeutics
Series C
Flare Therapeutics develops small molecule medicines that target transcription factor switch sites, with a pipeline initially focused on precision oncology.
Founded
2021Flare Therapeutics develops small molecule medicines that target transcription factor switch sites, with a pipeline initially focused on precision oncology.
Flare Therapeutics is a clinical-stage biotechnology company developing small molecule medicines that target transcription factors, a previously elusive target class. Its discovery platform identifies novel validated ligands to the undrugged proteome through an integrated chemistry and proteomics engine that enables ligand discovery directly from cells.
The company's pipeline is initially focused on precision oncology, led by FX-909, a first-in-class oral PPARG inhibitor in Phase 1B for locally advanced or metastatic urothelial cancer, and FX-111, a selective degrader targeting ARON for prostate cancer. Both programs are advancing toward later-stage clinical development.
Flare Therapeutics operates in the precision oncology market, where transcription factors have been recognized as high-value but undruggable targets. By enabling small molecule drugs against this target class, the company addresses a broad opportunity across prostate cancer, urothelial cancer, and other oncology indications driven by transcription factor dysregulation.
The company has secured a strategic discovery collaboration with Roche to address previously undrugged transcription factor targets in oncology, and it has raised a total of $290 million across three financing rounds. Its most recent $85 million Series C supports advancement of its lead programs toward clinical proof of concept.
Flare Therapeutics centers its discovery approach on switch sites, newly identified druggable regions within transcription factors that control predictable changes in gene expression. This switch-site biochemistry allows the company to address transcription factors that have long been considered undruggable, opening a new therapeutic space beyond conventional target classes.
The company combines a best-in-biotech chemistry and proteomics engine with ligand discovery performed directly from cells, which improves the physiological relevance of its drug candidates. Its scientific founders contribute deep expertise in transcription factor structure, genetics, and drug discovery, supporting a pipeline of first-in-class programs in precision oncology.